Results 151 to 160 of about 240,123 (312)

‘I'd rather have worse gums than worse lungs’: Young people's views of nicotine pouches in the UK

Addiction, EarlyView.
Abstract Background and aims Nicotine pouches entered the UK market in 2019. Although research has shown that young people's prevalence of use has been low, it has been reported to be increasing and a cause for concern. This paper reports the findings of the first qualitative study in the UK to explore the views of 14–16 year olds' knowledge, awareness
Andy MacGregor, Jessica Shields, Asiya Hamid, Eleanor Holman, Hannah Biggs, Sarah Minty, Jamie Pearce, Allison Ford   +7 more
wiley   +1 more source

Estimating thresholds for risk of cannabis use disorder using standard delta‐9‐tetrahydrocannabinol (THC) units

Addiction, EarlyView.
Abstract Background and aims Lower risk guidelines for safer levels of cannabis use could help to reduce the health burden posed by cannabis use disorder (CUD). We aimed to estimate risk thresholds for CUD based on delta‐9‐tetrahydrocannabinol (THC) consumption using standard THC units (1 unit = 5 mg THC).
Rachel Lees Thorne, Will Lawn, Kat Petrilli, Katie Trinci, Anya Borissova, Shelan Ofori, Claire Mokrysz, H. Valerie Curran, Lindsey A. Hines, Tom P. Freeman   +9 more
wiley   +1 more source

Outdated tools, underestimated harm: Modernizing cannabis surveillance in a post‐legalization era

Addiction, EarlyView.
Abstract Background Canada's 2018 legalization of non‐medical cannabis was positioned as a public health initiative, intended to shift cannabis use from criminalization to regulation. Since then, cannabis access and consumption have grown significantly but the systems used to monitor cannabis‐related harms have not kept pace.
Anees Bahji
wiley   +1 more source

Detecting cannabis use reduction through biochemical verification of urinary cannabinoids: An aggregated analysis of cannabis use disorder treatment trials examining average reductions and individual cut‐points

Addiction, EarlyView.
Abstract Background and aims Currently, there is no data‐driven cannabis reduction metric using biochemical verification, which represents a significant gap in cannabis harm reduction research, treatment and policy. Using aggregated data from 7 cannabis use disorder treatment trials, the aims of this analysis were to 1) determine if decreases in self ...
Erin A. McClure, Brian Neelon, Rachel L. Tomko, Ashley Dowd, Kevin M. Gray, Aimee L. McRae‐Clark, Nathaniel Baker   +6 more
wiley   +1 more source

Varenicline for cannabis use disorder: A randomized controlled trial

Addiction, EarlyView.
Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...
Aimee L. McRae‐Clark, Kevin M. Gray, Nathaniel L. Baker, Brian J. Sherman, Bryan Tolliver, Jessica Burt, Alonzo Steplight, Elizabeth Chapman, Amanda Wagner   +8 more
wiley   +1 more source

Commentary on Borodovsky et al.: Enhancing research on THC quantification—Consumer awareness through accurate labelling

Addiction, Volume 120, Issue 4, Page 686-687, April 2025.
Rachel Lees Thorne, Tom P. Freeman
wiley   +1 more source

Trends in fentanyl‐containing drug samples seized by law enforcement agencies across Canada

Addiction, EarlyView.
Abstract Background and aims Canada's drug toxicity crisis has been largely attributed to a volatile fentanyl‐dominated unregulated drug supply with increasing reports of fentanyl detected in combination with benzodiazepines, stimulants and xylazine.
Shaleesa Ledlie, Ria Garg, Pamela Leece, Gillian Kolla, Elaine Hyshka, Mina Tadrous, Tara Gomes   +6 more
wiley   +1 more source

To Cannabis or Not to Cannabis?

Swiss Medical Forum ‒ Schweizerisches Medizin-Forum, 2015
openaire   +1 more source

Transcriptome assemblies for two drug-type cannabis chemotypes by long-read RNA sequencing. [PDF]

Plant Genome
Berkowitz O, Jost R, Ng S, Bacic A, Whelan J, Lewsey MG.   +5 more
europepmc   +1 more source

Hippocampal subfield differences in people with and without recreational ketamine use: Insights from multi‐modal neuroimaging

Addiction, EarlyView.
Abstract Background and aims Recreational ketamine use has increased globally and is associated with psychiatric and cognitive concerns. The hippocampus in preclinical models shows damage and working‐memory disruption with repeated dosing. However, whether specific hippocampal subregions may differ in people with chronic ketamine use remains unclear ...
Yi‐Hsuan Liu, Chia‐Chun Hung, Marc N. Potenza, Kun‐Hsien Chou, Pei‐Lin Lee, Chu‐Chung Huang, Chiang‐Shan R. Li, Tony Szu‐Hsien Lee, Ching‐Po Lin   +8 more
wiley   +1 more source